Phaseline

Companies › ZetrOZ

ZetrOZ: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 1, 2 Phase 4; Immunology, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Diclofenac
Cyclooxygenase inhibitor
PTGS2, PTGS1Phase 1Bone Fracture; Osteoarthritis; Blood Gas Analysis; Elbow Pain–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06918340DiclofenacPhase 4Blood Gas AnalysisOtherDec 2024
NCT05883241DiclofenacPhase 1Bone FractureOtherFeb 2026
NCT05254574DiclofenacPhase 1OsteoarthritisImmunologyMay 2026
NCT06373978DiclofenacPhase 4Elbow PainOtherJun 2027

Targets

PTGS2 (1) PTGS1 (1)

Companies with the same targets

Caribou Biosciences Sana Biotechnology Laboratorios Silanes S.A. de C.V. Brainfarma Industria Química e Farmacêutica S/A AFT Pharmaceuticals Sirnaomics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.